`The GI market recently entered a crucial phase, with mounting commercial pressures affecting revenue generation and causing market participants to reconsider strategies,` says Visiongain report
Released on = February 1, 2006, 4:20 am
Press Release Author = Visiongain
Industry = Pharmaceuticals
Press Release Summary = San Francisco, CA and London, UK; 11 January 2006: The purpose of this visiongain report is to examine the prospects of the world gastrointestinal market. The gastrointestinal (GI) disorders market is one of the largest and most important in the pharmaceutical industry, generating revenues of over $16 billion in 2004. Report author Dr Gordon Low said: \" the gastrointestinal market is large and fragmented, but with continued opportunities for high revenue generation, despite increasing commercial pressures.\"
Press Release Body = In 2004, seven GI drugs achieved blockbuster revenues, with the dominant class being the proton pump inhibitors. Visiongain concludes that the GI market is going through a period of transition, with generic competition and OTC switching having a profound effect on the market. By 2011, total revenues for the leading GI drugs are likely to have declined to approximately $11 billion worldwide.
Clearly, the GI market is facing great challenges in terms of internal competition and patent expiration, with a mounting generic threat. There are also unmet needs that provide commercial opportunities. This visiongain report examines the GI market critically through a comprehensive review of available information, including that from commercial databases, consultation with the industry, company reports, business/industry news and consultation with international experts on GI disorders. Visiongain applied techniques such as financial forecasting, SWOT analysis and the assessment of unmet needs to provide a comprehensive market report with detailed analyses and informed opinion.
In particular, this visiongain report concentrates on revenue trends in the world gastrointestinal market between 2005-2011, patent expiry and generic substitution, an assessment of prescription-to-OTC switching and lifecycle management strategies. Furthermore, the report covers pipeline products, with an analysis of the prospects for these agents.
ENDS Notes for editors: To receive your complimentary overview of this report please send an email to Sara Peerun sara.peerun@visiongain.com, telephone Sara on +44 (0) 20 8767 6711 or visit the media section on http://www.visiongainintelligence.com/reportDetail.aspx?reportId
Web Site = http://www.visiongainintelligence.com
Contact Details = Visiongain 40, Tooting High Street London SW17 0RG
2022
